Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1485-1497

  Saidi, Hela ^a   Jenabian, Mohammad Ali ^b   Belec, Laurent ^c  

^a CEA   (France)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ALPHA INTERFERON; CD209 ANTIGEN; COLONY STIMULATING FACTOR 1; CYANOVIRIN N; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE GENITAL SYSTEM; GENITAL TRACT INFLAMMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MICROENVIRONMENT; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSONIZATION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPERM; T LYMPHOCYTE; TARGET CELL; VAGINA EPITHELIUM; VAGINA MUCOSA; VAGINAL LAVAGE; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG DESIGN; EPITHELIAL CELLS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MACACA; MALE; RECEPTORS, CCR5; SEMEN; VAGINA; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84868525568     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0049     Document Type: Article

References (153)

1. UNAIDS: World AIDS Day Report, www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2216-WorldAIDSday-report-2011- en.pdf. 2011.
2. Halperin DT, Mugurungi O, Hallett TB, et al.: A surprising prevention success: Why did the HIV epidemic decline in Zimbabwe? PLoS Med 2011;8:e1000414.
3. Bunnell R, Ekwaru JP, Solberg P, et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006;20:85-92.
4. Serwadda D, Gray RH, Sewankambo NK, et al.: Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: A nested case-control study in Rakai, Uganda. J Infect Dis 2003;188:1492-1497.
5. Katz IT and Wright AA: Circumcision-a surgical strategy for HIV prevention in Africa. N Engl J Med 2008;359:2412-2415.
6. Grant RM, Lama JR, Anderson PL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
7. Celum CL: HIV preexposure prophylaxis: New data and potential use. Top Antivir Med 2011;19:181-185.
8. Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
9. Baeten J, Donnell D, Ndase P, et al.: ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women. The Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2012.
10. Mujugira A, Baeten JM, Donnell D, et al.: Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 2011;6:e25828.
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
12. Stone A: Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 2002;1:977-985.
13. Watkins DI, Burton DR, Kallas EG, Moore JP, and Koff WC: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-621.
14. Feldblum PJ, Adeiga A, Bakare R, et al.: SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
15. Ramjee G, Govinden R, Morar NS, and Mbewu A: South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med 2007;4:e235.
16. Van Damme L, Govinden R, Mirembe FM, et al.: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-472.
17. Skoler-Karpoff S, Ramjee G, Ahmed K, et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-1987.
18. Saidi H: Microbicides: An emerging science of HIV-1 prevention in women-15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 February 2008. Rev Med Virol 2009;19:69-76.
19. Turville SG, Aravantinou M, Miller T, et al.: Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008;3:e3162.
20. Kell PD, Barton SE, Edmonds DK, and Boag FC: HIV infection in a patient with Meyer-Rokitansky-Kuster-Hauser syndrome. J R Soc Med 1992;85:706-707.
21. Miller CJ, Alexander NJ, Vogel P, Anderson J, and Marx PA: Mechanism of genital transmission of SIV: A hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J Med Primatol 1992;21:64-68.
22. Louissaint NA, Fuchs EJ, Bakshi RP, et al.: Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. J Infect Dis 2012;205:725-732.
23. Cavellani CL, Rocha LP, da Silva Rosa SC, et al.: The influence of AIDS on the morphometric and immune status of the uterine cervix of autopsied patients. Curr HIV Res 2011;9:606-612.
24. Nazli A, Chan O, Dobson-Belaire WN, et al.: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010;6: e1000852.
25. Margolis L and Shattock R: Selective transmission of CCR5-utilizing HIV-1: The 'gatekeeper' problem resolved? Nat Rev Microbiol 2006;4:312-317.
26. Dezzutti CS, Guenthner PC, Cummins JE Jr, et al.: Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001;183:1204-1213.
27. Furuta Y, Eriksson K, Svennerholm B, et al.: Infection of vaginal and colonic epithelial cells by the human immu-nodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glyco-protein gp120. Proc Natl Acad Sci USA 1994;91:12559-12563.
28. Keller MJ and Herold BC: Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm Dis 2009;36:S92-S95.
29. Promadej-Lanier N, Srinivasan P, Curtis K, et al.: Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques. Virology 2008;375:492-503.
30. Poonia B, Walter L, Dufour J, Harrison R, Marx PA, and Veazey RS: Cyclic changes in the vaginal epithelium of normal rhesus macaques. J Endocrinol 2006;190:829-835.
31. Gumbi PP, Nkwanyana NN, Bere A, et al.: Impact of mu-cosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol 2008;82:8529-8536.
32. Zara F, Nappi RE, Brerra R, Migliavacca R, Maserati R, and Spinillo A: Markers of local immunity in cervico-vaginal secretions of HIV infected women: Implications for HIV shedding. Sex Transm Infect 2004;80:108-112.
33. Ryckman KK, Williams SM, Krohn MA, and Simhan HN: Racial differences in cervical cytokine concentrations between pregnant women with and without bacterial vagi-nosis. J Reprod Immunol 2008;78:166-171.
34. Fidel PL, Jr., Luo W, Steele C, Chabain J, Baker M, and Wormley F Jr: Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999;67:3135-3140.
35. Ma Z, Lu FX, Torten M, and Miller CJ: The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin Immunol 2001;100:240-249.
36. Vishwanathan SA, Guenthner PC, Lin CY, et al.: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011;57:261-264.
37. Baeten JM, Lavreys L, and Overbaugh J: The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007;45:360-369.
38. Hel Z, Stringer E, and Mestecky J: Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010;31:79-97.
39. Marx PA, Spira AI, Gettie A, et al.: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-1089.
40. Stringer E and Antonsen E: Hormonal contraception and HIV disease progression. Clin Infect Dis 2008;47:945-951.
41. Stringer EM, Kaseba C, Levy J, et al.: A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144 e141-e148.
42. Ferre AL, Hunt PW, McConnell DH, et al.: HIV controllers with HLA-DRB1 13 and HLA-DQB1 06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol 2010; 84:11020-11029.
43. Liu J, Keele BF, Li H, et al.: Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010;84:10406-10412.
44. Cheng-Mayer C, Huang Y, Gettie A, et al.: Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 2011;25:1833-1841.
45. Barouch DH, Klasse PJ, Dufour J, Veazey RS, and Moore JP: Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012;109:8694-8698.
46. Dayal MB, Wheeler J, Williams CJ, and Barnhart KT: Disruption of the upper female reproductive tract epithelium by nonoxynol-9. Contraception 2003;68:273-279.
47. Chenine AL, Siddappa NB, Kramer VG, et al.: Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010;201:1155-1163.
48. Saidi H, Magri G, Nasreddine N, Requena M, and Belec L: R5-and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: Implication for mechanisms of sexual transmission. Virology 2007;358:55-68.
49. Fontenot D, He H, Hanabuchi S, et al.: TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proc Natl Acad Sci USA 2009;106:16776-16781.
50. Bouhlal H, Chomont N, Requena M, et al.: Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007;178:1086-1095.
51. Eslahpazir J, Jenabian MA, Bouhlal H, et al.: Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervi-covaginal secretions. Clin Vaccine Immunol 2008;15:872-884.
52. Saidi H, Magri G, Carbonneil C, Nasreddine N, Requena M, and Belec L: IFN-gamma-activated monocytes weakly produce HIV-1 but induce the recruitment of HIV-sensitive T cells and enhance the viral production by these recruited T cells. J Leukoc Biol 2007;81:642-653.
53. Li Q, Estes JD, Schlievert PM, et al.: Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458:1034-1038.
54. Haase AT: Targeting early infection to prevent HIV-1 mu-cosal transmission. Nature 2010;464:217-223.
55. Zhang Z, Schuler T, Zupancic M, et al.: Sexual transmission and propagation of SIV and HIV in resting and activated CD4 + T cells. Science 1999;286:1353-1357.
56. Geijtenbeek TB, Kwon DS, Torensma R, et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
57. Hladik F, Sakchalathorn P, Ballweber L, et al.: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26:257-270.
58. Hirbod T, Kaldensjo T, and Broliden K: In situ distribution of HIV-binding CCR5 and C-type lectin receptors in the human endocervical mucosa. PLoS One 2011;6:e25551.
59. Hirbod T, Kaldensjo T, Lopalco L, et al.: Abundant and superficial expression of C-type lectin receptors in ecto-cervix of women at risk of HIV infection. J Acquir Immune Defic Syndr 2009;51:239-247.
60. Spira AI, Marx PA, Patterson BK, et al.: Cellular targets of infection and route of viral dissemination after an in-travaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-225.
61. Collins KB, Patterson BK, Naus GJ, Landers DV, and Gupta P: Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000;6:475-479.
62. Hu J, Gardner MB, and Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-6095.
63. Patterson BK, Landay A, Siegel JN, et al.: Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002;161:867-873.
64. Chehimi J, Luo Q, Azzoni L, et al.: HIV-1 transmission and cytokine-induced expression of DC-SIGN in human mono-cyte-derived macrophages. J Leukoc Biol 2003;74:757-763.
65. Nguyen DG and Hildreth JE: Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 2003;33:483-493.
66. Lambert AA, Gilbert C, Richard M, Beaulieu AD, and Tremblay MJ: The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans-and cis-infection pathways. Blood 2008;112:1299-1307.
67. Bobardt MD, Chatterji U, Selvarajah S, et al.: Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007;81:395-405.
68. Bobardt MD, Saphire AC, Hung HC, et al.: Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003;18:27-39.
69. Saphire AC, Bobardt MD, Zhang Z, David G, and Gallay PA: Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 2001;75:9187-9200.
70. de Parseval A, Bobardt MD, Chatterji A, et al.: A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem 2005;280:39493-39504.
71. de Witte L, Nabatov A, and Geijtenbeek TB: Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol Med 2008;14:12-19.
72. van der Vlist M, van der Aar AM, Gringhuis SI, and Geij-tenbeek TB: Innate signaling in HIV-1 infection of dendritic cells. Curr Opin HIV AIDS 2011;6:348-352.
73. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, and Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010;11:419-426.
74. Miller CJ, Vogel P, Alexander NJ, Sutjipto S, Hendrickx AG, and Marx PA: Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am J Pathol 1992;141:655-660.
75. Jenabian MA, Saidi H, Charpentier C, et al.: In vitro syn-ergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J Antimicrob Chemother 2009;64:1192-1195.
76. Vermeire K, Brouwers J, Van Herrewege Y, et al.: CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res 2008;6:246-256.
77. Saïdi H, Jenabian MA, and Bélec L: Early events in vaginal HIV transmission: Implications in microbicide development. Future Virol 2009;4:259-269.
78. Nathan C: Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 2006;6:173-182.
79. Nkwanyana NN, Gumbi PP, Roberts L, et al.: Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononu-clear cells in the female genital tract. Immunology 2009; 128:e746-e757.
80. Belec L, Gherardi R, Payan C, et al.: Proinflammatory cy-tokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995;7:568-574.
81. Saidi H, Melki MT, and Gougeon ML: HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. PLoS One 2008;3:e3601.
82. Gougeon ML, Melki MT, and Saidi H: HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell Death Differ 2012;19:96-106.
83. Borde C, Barnay-Verdier S, Gaillard C, Hocini H, Marechal V, and Gozlan J: Stepwise release of biologically active HMGB1 during HSV-2 infection. PLoS One 2011;6:e16145.
84. Nowak P, Barqasho B, and Sonnerborg A: Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. AIDS 2007;21:869-871.
85. Ploquin MJ, Diop OM, Sol-Foulon N, et al.: DC-SIGN from African green monkeys is expressed in lymph nodes and mediates infection in trans of simian immunodeficiency virus SIVagm. J Virol 2004;78:798-810.
86. Perreau M, Pantaleo G, and Kremer EJ: Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008;205:2717-2725.
87. Requena M, Bouhlal H, Nasreddine N, et al.: Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous im-munoglobulins. Immunology 2008;123:508-518.
88. Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, et al.: HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog 2010;6:e1000740.
89. Yu HJ, Reuter MA, and McDonald D: HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog 2008;4:e1000134.
90. Saidi H, Carbonneil C, Magri G, Eslahpazir J, Sekaly RP, and Belec L: Differential modulation of CCR5-tropic human immunodeficiency virus-1 transfer from macrophages towards T cells under interleukin-4/interleukin-13 microenvironment. Hum Immunol 2010;71:1-13.
91. Said EA, Dupuy FP, Trautmann L, et al.: Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010;16:452-459.
92. Modlin RL, Pirmez C, Hofman FM, et al.: Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989; 339:544-548.
93. McMenamin C, Pimm C, McKersey M, and Holt PG: Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science 1994;265:1869-1871.
94. Lehner T, Mitchell E, Bergmeier L, et al.: The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000;30:2245-2256.
95. Keele BF and Estes JD: Barriers to mucosal transmission of immunodeficiency viruses. Blood 2011;118:839-846.
96. Salazar-Gonzalez JF, Bailes E, Pham KT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008;82:3952-3970.
97. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557.
98. Fisher AG, Ensoli B, Looney D, et al.: Biologically diverse molecular variants within a single HIV-1 isolate. Nature 1988;334:444-447.
99. Etemad B, Fellows A, Kwambana B, et al.: Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol 2009; 83:9694-9708.
100. Saag MS, Hahn BH, Gibbons J, et al.: Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988;334:440-444.
101. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-1272.
102. Gnanakaran S, Bhattacharya T, Daniels M, et al.: Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 2011;7:e1002209.
103. Wilen CB, Parrish NF, Pfaff JM, et al.: Phenotypic and im-munologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 2011;85:8514-8527.
104. Parrish NF, Wilen CB, Banks LB, et al.: Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012;8: e1002686.
105. Ochsenbauer C, Edmonds TG, Ding H, et al.: Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012;86:2715-2728.
106. Li H, Bar KJ, Wang S, et al.: High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6:e1000890.
107. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al.: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206:1273-1289.
108. Chomont N, Hocini H, Gresenguet G, et al.: Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS 2007; 21:153-162.
109. Miller CJ and Hu J: T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. J Infect Dis 1999;179(Suppl 3):S413-S417.
110. Zhang H, Dornadula G, Beumont M, et al.: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-1809.
111. Pillai SK, Good B, Pond SK, et al.: Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005;79:1734-1742.
112. Berlier W, Bourlet T, Lawrence P, et al.: Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV. J Med Virol 2005;77:465-474.
113. Saba E, Grivel JC, Vanpouille C, et al.: HIV-1 sexual transmission: Early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3:280-290.
114. Greenier JL, Miller CJ, Lu D, et al.: Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol 2001;75:3753-3765.
115. Butler DM, Delport W, Kosakovsky Pond SL, et al.: The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med 2011;2:18re11.
116. Miller CJ, Marthas M, Torten J, et al.: Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol 1994;68:6391-6400.
117. Miller CJ, McChesney M, and Moore PF: Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992;67:628-634.
118. Salle B, Brochard P, Bourry O, et al.: Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010;202:337-344.
119. Denton PW, Krisko JF, Powell DA, et al.: Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010;5:e8829.
120. Lai SK, Hida K, Shukair S, et al.: Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009;83:11196-11200.
121. O'Hanlon DE, Moench TR, and Cone RA: In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis 2011;11:200.
122. O'Hanlon DE, Lanier BR, Moench TR, and Cone RA: Cer-vicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli. BMC Infect Dis 2010;10:120.
123. Lederman MM, Offord RE, and Hartley O: Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006;6:371-382.
124. Brocca-Cofano E, McKinnon K, Demberg T, et al.: Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011;29:3310-3319.
125. Saidi H, Eslahpazir J, Carbonneil C, et al.: Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol 2006;177:5540-5549.
126. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, and Fowke KR: Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J Infect Dis 2009;199:1318-1322.
127. Bosinger SE, Li Q, Gordon SN, et al.: Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009;119:3556-3572.
128. Genesca M, Ma ZM, Wang Y, et al.: Live-attenuated lenti-virus immunization modulates innate immunity and inflammation while protecting RM from vaginal SIV challenge. J Virol 2012;77:3099-3118.
129. Estes JD, Gordon SN, Zeng M, et al.: Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 2008;180:6798-6807.
130. Gasper-Smith N, Crossman DM, Whitesides JF, et al.: Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: Implications for HIV-1 vaccine design. J Virol 2008;82:7700-7710.
131. Boasso A and Shearer GM: How does indoleamine 2, 3-dioxygenase contribute to HIV-mediated immune dysre-gulation. Curr Drug Metab 2007;8:217-223.
132. Hartner JC, Walkley CR, Lu J, and Orkin SH: ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 2009;10:109-115.
133. Chawla-Sarkar M, Lindner DJ, Liu YF, et al.: Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-249.
134. Munch J, Rucker E, Standker L, et al.: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007;131:1059-1071.
135. Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, and Robertson SA: Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012;188(5):2445-2454.
136. Hubert P, van den Brule F, Giannini SL, Franzen-Detrooz E, Boniver J, and Delvenne P: Colonization of in vitro-formed cervical human papillomavirus- associated (pre)neoplastic lesions with dendritic cells: Role of granulocyte/macro-phage colony-stimulating factor. Am J Pathol 1999;154:775-784.
137. Shen L, Fahey JV, Hussey SB, Asin SN, Wira CR, and Fanger MW: Synergy between IL-8 and GM-CSF in reproductive tract epithelial cell secretions promotes enhanced neutrophil chemotaxis. Cell Immunol 2004;230:23-32.
138. Tremellen KP, Seamark RF, and Robertson SA: Seminal transforming growth factor beta 1 stimulates granulocyte-macrophage colony-stimulating factor production and inflammatory cell recruitment in the murine uterus. Biol Reprod 1998;58:1217-1225.
139. Politch JA, Tucker L, Bowman FP, and Anderson DJ: Concentrations and significance of cytokines and other immunologic factors in semen of healthy fertile men. Hum Reprod 2007;22:2928-2935.
140. Kafka JK, Sheth PM, Nazli A, et al.: Endometrial epithelial cell response to semen from HIV-infected men during different stages of infection is distinct and can drive HIV-1-long terminal repeat. AIDS 2012;26:27-36.
141. Berlier W, Cremel M, Hamzeh H, et al.: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: Involvement in the sexual transmission of HIV. Hum Reprod 2006;21:1135-1142.
142. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection:2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
143. Bunge K, Macio I, Meyn L, et al.: The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781. J Acquir Immune Defic Syndr 2012;60:337-343.
144. Ceballos A, Remes Lenicov F, Sabatte J, et al.: Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J Exp Med 2009;206:2717-2733.
145. Jenabian MA, Saidi H, Charpentier C, et al.: Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Res Ther 2010;7:16.
146. Kazmi SH, Naglik JR, Sweet SP, et al.: Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006;13:1111-1118.
147. Herrera C, Cranage M, McGowan I, Anton P, and Shattock RJ: Colorectal microbicide design: Triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS 2011;25:1971-1979.
148. Keller MJ, Tuyama A, Carlucci MJ, and Herold BC: Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 2005;55:420-423.
149. Belec L, Jenabian MA, Charpentier C, and Saidi H: Combinatorial prevention of HIV transmission in women: The case for a vaginal microbicide. Future Microbiol 2011;6:731-737.
150. Lieberman-Blum SS, Fung HB, and Bandres JC: Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008;30:1228-1250.
151. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
152. Mori T and Boyd MR: Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001;45:664-672.
153. Singh IP and Chauthe SK: Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists:2004-2010. Expert Opin Ther Pat 2011;21:227-269.